Intézmény

St Bartholomew's Hospital

London, Egyesült KirályságHonlap

Más néven: The Royal Hospital of St Bartholomew

108futó vizsgálat
34lezárt vizsgálat
27 276publikáció (OpenAlex)

Futó vizsgálatok

Még nem toboroz
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
NCT07850063· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264· 3. fázis· CSL Behring· Forrás
Toboroz
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07771465· 3. fázis· Kardigan, Inc.· Forrás
Toboroz
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT07513376· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2)
NCT07165678· Queen Mary University of London· Forrás
Toboroz
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351· 1/2. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study
NCT06939374· Cryotherapeutics SA· Forrás
Toboroz
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07210723· 2/3. fázis· Kardigan, Inc.· Forrás
Toboroz
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
NCT07232602· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
NCT07284459· 2. fázis· Contineum Therapeutics· Forrás
Toboroz
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383· Vascutek Ltd.· Forrás
Toboroz
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· 3. fázis· Janssen Research & Development, LLC· Forrás
Meghívásos bevonás
Optical Coherence Tomography in Acute Vessel Evaluation
NCT07422688· Aarhus University Hospital Skejby· Forrás
Toboroz
Substrate Remodelling and Targeted Ablation in AF
NCT07047235· Barts & The London NHS Trust· Forrás
Toboroz
Clinical Investigation Evaluating the Performance, Safety and Clinical Benefit of the Endowave FlexAblate™ Microwave Ablation System in Patients Undergoing Lung Ablation Procedures.
NCT07291973· Endowave Ltd.· Forrás
Toboroz
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· 3. fázis· Pfizer· Forrás
Toboroz
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312· 3. fázis· Kura Oncology, Inc.· Forrás
Toboroz
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· 3. fázis· Relay Therapeutics, Inc.· Forrás
Toboroz
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· 3. fázis· Pfizer· Forrás
Toboroz
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
NCT07049926· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
NCT06891755· Apreo Health, Inc.· Forrás
Toboroz
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT06863272· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375· 2. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362· 2. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT06806852· 1. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895· 3. fázis· Eidos Therapeutics, a BridgeBio company· Forrás
Toboroz
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
NCT06884618· 1. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT06686394· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation
NCT06165510· Barts & The London NHS Trust· Forrás
Fut, nem toboroz
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
NCT06483334· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study to Obtain Imaging Data in 40 Patients Having Transcatheter Aortic Valve Implantation (TAVI)
NCT06596460· Barts & The London NHS Trust· Forrás
Toboroz
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069· 1. fázis· Eli Lilly and Company· Forrás

Showing 50 of 108.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Tüdőrák10 toboroz
Szívelégtelenség9 toboroz
Áttétes emlőrák6 toboroz
Hólyagrák6 toboroz
Prosztatarák6 toboroz
Koszorúér-betegség4 toboroz
Mielóma multiplex4 toboroz
Pitvarfibrilláció4 toboroz
Akut mieloid leukémia (AML)3 toboroz
Aortic stenosis3 toboroz
Gyermekkori daganatok3 toboroz
Gyomor- és nyelőcsőrák3 toboroz
Tripla negatív emlőrák3 toboroz
Vastagbélrák3 toboroz
Vesedaganat3 toboroz
Aortic aneurysm2 toboroz
Dilated cardiomyopathy2 toboroz
Elhízás2 toboroz
Fej-nyaki daganatok2 toboroz
Petefészekrák2 toboroz
Akut limfoid leukémia (ALL)1 toboroz
Amiloidózis1 toboroz
Hasnyálmirigyrák1 toboroz
Hipertrófiás kardiomiopátia1 toboroz
Hodgkin-limfóma1 toboroz
Idiopátiás tüdőfibrózis1 toboroz
Köpenysejtes limfóma1 toboroz
Krónikus limfoid leukémia (CLL)1 toboroz
Krónikus obstruktív tüdőbetegség (COPD)1 toboroz
Magas vérnyomás1 toboroz
Méhnyakrák1 toboroz
Mezotelióma1 toboroz
Mielodiszplasztikus szindróma (MDS)1 toboroz
Stroke (szélütés)1 toboroz
Szarkóma1 toboroz
Ventricular tachycardia1 toboroz
Zsírmáj (MASLD/MASH)1 toboroz

Lezárt vizsgálatok

Visszavonták
Multimodality Optical and Ultrasound Intravascular Imaging for Stent Optimization and Atheroma Assessment
NCT05753085· Barts & The London NHS Trust· Forrás
Lezárult
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
NCT06637423· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás
Leállították
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
NCT05949632· 1/2. fázis· Incyte Corporation· Forrás
Lezárult
VOLT-AF IDE Clinical Study
NCT06223789· Abbott Medical Devices· Forrás
Lezárult
Pilot Study of Hypertrophic Cardiomyopathy & Implantable Cardioverter Defibrillator Assessment: (Subcutaneous vs Transvenous)
NCT05938283· Barts & The London NHS Trust· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
Stereotactic Ablative Radiotherapy for the Treatment of Refractory Ventricular Tachycardia
NCT05696522· Barts & The London NHS Trust· Forrás
Lezárult
The TRAMPOLINE VT Study
NCT05152784· Barts & The London NHS Trust· Forrás
Lezárult
Improving AF Detection in Cryptogenic Stroke
NCT05007847· Barts & The London NHS Trust· Forrás
Lezárult
Apple Watch-led Surveillance of AF Recurrence After Catheter Ablation
NCT05016791· Barts & The London NHS Trust· Forrás
Lezárult
A Mechanistic Exploratory Study of AF-induced Cardiac Dysfunction and Symptoms
NCT04987723· Barts & The London NHS Trust· Forrás
Visszavonták
CONVERGE CAP Study-For The Treatment Of Symptomatic Persistent or Long-standing Persistent AF
NCT04239534· AtriCure, Inc.· Forrás
Lezárult
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
NCT05076149· 3. fázis· Vertex Pharmaceuticals Incorporated· Forrás
Lezárult
Portico Valve-in-Valve Retrospective Registry
NCT05002088· Abbott Medical Devices· Forrás
Lezárult
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
NCT05033080· 3. fázis· Vertex Pharmaceuticals Incorporated· Forrás
Lezárult
Registry of Asthma Patients Initiating DUPIXENT®
NCT04287621· Regeneron Pharmaceuticals· Forrás
Lezárult
Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT
NCT04173533· 3. fázis· University of Birmingham· Forrás
Lezárult
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
NCT03898180· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT03900598· 1. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
NCT03782207· Hoffmann-La Roche· Forrás
Lezárult
Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients
NCT07022626· Barts & The London NHS Trust· Forrás
Lezárult
Atezolizumab Trial in Endometrial Cancer - AtTEnd
NCT03603184· 3. fázis· Mario Negri Institute for Pharmacological Research· Forrás
Lezárult
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
NCT03511664· 3. fázis· Endocyte· Forrás
Lezárult
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
NCT03268954· 3. fázis· Takeda· Forrás
Lezárult
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
NCT03301220· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
NCT03277105· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease
NCT03168776· Sino Medical Sciences Technology Inc.· Forrás
Lezárult
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
NCT03040999· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab
NCT02926196· 3. fázis· Istituto Oncologico Veneto IRCCS· Forrás
Lezárult
Cryo Global Registry
NCT02752737· Medtronic Cardiac Ablation Solutions· Forrás
Lezárult
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
NCT02101788· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Lezárult
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers
NCT01597219· 2. fázis· University College, London· Forrás
Lezárult
Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours
NCT01726374· 3. fázis· Institute of Cancer Research, United Kingdom· Forrás

Regiszterbeli névváltozatok (33)

A vizsgálati regiszterek ezeken a neveken tartják nyilván az intézményt. Minden sor egy regiszterbejegyzés: a címe és az alatta nyilvántartott vizsgálatok.

St. Bartholomew's Hospital
London, EC1A 7BE
109 vizsgálat
Saint Bartholomew's Hospital
London, EC1A 7BE
6 vizsgálat
St Bartholomew's Hospital
City of London, London EC1A7BE
2 vizsgálat
- NCT05007847Improving AF Detection in Cryptogenic Stroke
- NCT05016791Apple Watch-led Surveillance of AF Recurrence After Catheter Ablation
St Bartholomew's Hospital - Cardiac Research Office
London, EC1A 7BE
2 vizsgálat
- NCT06979375A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
  Contact: Novo Nordisk
- NCT06979362A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
  Contact: Novo Nordisk
St Bartholomew's Hospital - Cardiology
London, EC1A 7BE
2 vizsgálat
- NCT06979375A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
  Contact: Novo Nordisk
- NCT06979362A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
  Contact: Novo Nordisk
Saint Bartholomew s Hospital - London (Site 0386)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT03898180Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
St Bartholomew's Hospital - PPDS
London, Greater London EC1A 7BE
1 vizsgálat
- NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
  Contact: Nikki Nepomuceno
St Bartholomew's Hospitals
London
1 vizsgálat
- NCT04550104A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
  Contact: CTRU CONCORDE
St Bartholomew s Hospital (Site 0040)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT06686394Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
  Contact: Study Coordinator
St Bartholomew s Hospital (Site 0061)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT06637423A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
St Bartholomew's Hospital (Site 0400)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT07513376A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
  Contact: Study Coordinator
St Bartholomew's Hospital (Site 0749)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT06863272A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
  Contact: Study Coordinator
St Bartholomew's Hospital (Site 0751)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT07419295A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
  Contact: Study Coordinator
St Bartholomew s Hospital (Site 0925)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT06925737A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  Contact: Study Coordinator
St Bartholomew's Hospital (Site 1000)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT06307431A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
St Bartholomew s Hospital (Site 1008)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT03711032Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
St Bartholomew s Hospital (Site 1205)
London, EC1A 7BE
1 vizsgálat
- NCT03040999Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
St Bartholomew's Hospital (Site 1206)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT05562830A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
St Bartholomew's Hospital (Site 1508)
London, England EC1A 7BE
1 vizsgálat
- NCT04895358Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
St Bartholomew s Hospital (Site 1700)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT06833073A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
  Contact: Study Coordinator
St Bartholomew's Hospital (Site 1901)
London, London, City of EC1A7BE
1 vizsgálat
- NCT06422143Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
  Contact: Study Coordinator
St Bartholomew s Hospital (Site 2200)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  Contact: Study Coordinator
St Bartholomew's Hospital (Site 2206)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
St Bartholomew's Hospital (Site 2804)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
St Bartholomew's Hospital (Site 4001)
London, London, City of EC1A7BE
1 vizsgálat
- NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  Contact: Study Coordinator
St Bartholomew s Hospital (Site 4206)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT06483334A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
St Bartholomew s Hospital (Site 5206)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT07232602KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
  Contact: Study Coordinator
St Bartholomew s Hospital (Site 5302)
London, London, City of EC1A 7BE
1 vizsgálat
- NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  Contact: Study Coordinator
St Bartholomew's Hospital (Site 5401)
London, London, City of EC1A7BE
1 vizsgálat
- NCT07049926Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
  Contact: Study Coordinator
St. Bartholomew's Hospital,Substudy-01
London, E1 1BB
1 vizsgálat
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
St. Bartholomew's Hospital,Substudy-02
London, E1 1BB
1 vizsgálat
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
St. Bartholomew's Hospital,Substudy-03
London, E1 1BB
1 vizsgálat
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
St Bartholomew's Hospital - Dept of Haematology
London, EC1A 7BE

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

Hipertrófiás kardiomiopátia26 munka · 2 vizsgálat
Dilated cardiomyopathy17 munka · 3 vizsgálat
Aortic stenosis14 munka · 5 vizsgálat
Ventricular tachycardia11 munka · 3 vizsgálat
Fabry-betegség3 munka · 0 vizsgálat

Intézményadatok: ROR 00nh9x179 (CC0-1.0)Frissítve: 2026. nov. 12.

Hibát jelzek